2m 2m 2m 2m 2m 2m 2m
GT BIOPHARMA (GTBP)
NASDAQ
$0.46-$0.004 (-0.90%)
Price as of Jun 03, 2026 7:16 PM EDT- $17.2MMarket Cap
- -83.43%1-Year Change
- BiotechnologyIndustry
GT BIOPHARMA (GTBP)
$0.46-$0.004 (-0.90%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 8.9M +4.48% | 8.6M +20.48% | 7.1M -42.87% | 12.4M -74.03% | |
Research and Development Expense | -3.5M -40.12% | -5.8M -10.33% | -6.5M -26.61% | -8.8M -8.13% | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 8.9M +4.48% | 8.6M -36.90% | 13.6M -36.13% | 21.3M -55.64% | |
Operating Profit | -12.4M -13.52% | -14.4M +5.80% | -13.6M -36.13% | -21.3M -63.04% | |
Interest Income | 123,000 -69.40% | 402,000 -48.46% | 780,000 +167.12% | 292,000 N/A | |
Interest Expense | N/A N/A | N/A N/A | -213,000 +2,562.50% | -8,000 N/A | |
Interest Income and Expense and Net | 123,000 -69.40% | 402,000 -29.10% | 567,000 +99.65% | 284,000 N/A | |
Total Nonoperating Income and Expense | -15.9M -1,425.46% | 1.2M -79.90% | 6.0M +1,502.95% | 373,000 +174.90% | |
Income before Taxes | -34.4M +139.83% | -14.4M +5.80% | -13.6M -36.13% | -21.3M -63.04% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -34.4M +161.73% | -13.2M +73.25% | -7.6M -63.62% | -20.9M -64.00% | |
Net Income from Continuing Operations Applicable to Common | -34.4M +161.73% | -13.2M +73.25% | -7.6M -63.62% | -20.9M -64.00% | |
Basic EPS and Net Income | -6.68 -3.75% | -6.94 +23.05% | -5.64 +754.55% | -0.66 -67.96% | |
Diluted EPS and Net Income | -6.68 -3.75% | -6.94 +23.05% | -5.64 +754.55% | -0.66 -67.96% | |
Basic Weighted Average Shares | 5.5M +190.57% | 1.9M +40.78% | 1.3M -95.77% | 31.9M +13.19% | |
Diluted Weighted Average Shares | 5.5M +190.57% | 1.9M +40.78% | 1.3M -95.77% | 31.9M +13.19% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 6.8M +72.39% | 4.0M +266.17% | 1.1M -80.98% | 5.7M -36.75% | |
Short-Term Investments | N/A N/A | N/A N/A | 12.9M +18.98% | 10.8M -52.91% | |
Cash and Cash Equivalents and Short-Term Investments | 6.8M +72.39% | 4.0M -71.72% | 14.0M -15.36% | 16.5M -48.38% | |
Total Current Assets | 8.1M +91.54% | 4.2M -69.89% | 14.1M -15.13% | 16.6M -48.52% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 634,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Assets | 8.1M +91.54% | 4.2M -70.00% | 14.1M -15.70% | 16.7M -47.97% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 2.5M +7,964.52% | |
Total Current Liabilities | 2.3M -60.71% | 5.9M -11.02% | 6.6M +34.33% | 4.9M -51.87% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 1.0M -98.41% | 62.9M +30.23% | |
Total Long-Term Liabilities | 150,000 -97.41% | 5.8M -90.19% | 59.1M +92,243.75% | 64,000 N/A | |
Total Liabilities | 2.3M -60.71% | 5.9M -11.02% | 6.6M +32.61% | 5.0M -51.24% | |
Retained Earnings | -723.9M +4.12% | -695.2M +1.93% | -682.1M +1.13% | -674.5M +3.20% | |
Total Stockholders Equity | N/A N/A | -1.7M -122.34% | 7.5M -36.29% | 11.7M -46.44% | |
Total Shares Outstanding | 25.5M +1,042.81% | 2.2M +61.83% | 1.4M -95.78% | 32.7M +2.06% | |
Cash Flow | |||||
Cash from Operating Activities | -12.9M +0.08% | -12.9M +45.77% | -8.9M -41.83% | -15.2M -2.49% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | 12.9M +741.76% | -2.0M -116.54% | 12.1M +152.71% | |
Dividends Paid | 229,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 15.8M +430.07% | 3.0M -52.52% | 6.3M +2,898.21% | -224,000 -100.53% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -558.42% +289.07% | -143.53% +191.37% | -49.26% -42.32% | -85.41% -72.15% | |
Return on Equity | N/A N/A | -453.39% +473.23% | -79.09% -36.29% | -124.15% -108.05% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 3.50 +387.52% | 0.72 -66.16% | 2.12 -36.82% | 3.35 +6.96% | |
Cash Ratio | 2.94 +338.75% | 0.67 +311.43% | 0.16 -85.83% | 1.15 +31.39% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 5.57 +152.66% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 3.91 +160.10% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow